La vendita allo scoperto per SIGNA Sports United dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SIGNA Sports United. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SIGNA Sports United (OTC:SSUNF) Azioni, Report sulle vendite allo scoperto

SIGNA Sports United NV is a group of specialist sports webshops powered by its sports commerce and technology platform. The company's segment includes Tennis; Bike and Outdoor and Teamsport. It generates maximum revenue from the Bike and Outdoor segment. Geographically, it derives a majority of revenue from Germany.

SIGNA SPORTS UNITED N.V. by SIGNA Sports United N.V.

SIGNA Sports United NV

<ul>
<li>BorgWarner to supply Exhaust Gas Recirculation (EGR) components for OEM's passenger and light commercial vehicle platforms for combustion and hybrid applications</li>
<li>EGR system reduces NOx emissions and improves fuel economy to help meet environmental standards</li>
<li>EGR production extends through 2029</li>
</ul>

News

Contracts

BorgWarner Extends Four Exhaust Gas Recirculation Contracts With North American OEM; Financial Terms Not Disclosed

Hovde Group analyst Brendan Nosal upgrades Bank First (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFC#NASDAQ">BFC</a>) from Market Perform to Outperform.

Upgrades

Analyst Ratings

Hovde Group Upgrades Bank First to Outperform

Biotech

General

THAR

Tharimmune Highlights Presentation Of Data On TH104 Metabolic Profile At Digestive Disease Week

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fiecure.com%2F&amp;esheet=54249333&amp;newsitemid=20250506379506&amp;lan=en-US&amp;anchor=iECURE&amp;index=1&amp;md5=73da240a6aae34cec7d349a9e6455d93">iECURE</a>, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that initial data from the first participant to complete the ongoing OTC-HOPE clinical trial evaluating in vivo gene editing candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 12 – 17, 2025 in New Orleans and the European Society of Human Genetics (ESHG) Conference taking place May 24 – 27, 2025 in Milan, Italy. In addition to the clinical data, iECURE will also participate in a symposium session highlighting the company's clinical advances in genome editing at ASGCT.
The poster, oral and symposium presentations will build upon data the company <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fiecure.com%2Fnews%2Fiecure-reports-complete-clinical-response-in-first-infant-dosed-with-its-in-vivo-gene-editing-candidate-ecur-506-in-an-ongoing-phase-1-2-clinical-trial-in-ornithine-transcarbamylase-otc-deficiency%2F&amp;esheet=54249333&amp;newsitemid=20250506379506&amp;lan=en-US&amp;anchor=reported&amp;index=2&amp;md5=cc17c66826b478effbcf7ca524c338de">reported</a> in January 2025 showing that the first infant dosed in the ongoing OTC-HOPE study experienced a complete clinical response as per study protocol.
ASGCT Details:
Poster Title: Initial clinical results from OTC-HOPE, the first in vivo, liver directed, AAV-mediated gene insertion study in neonatal OTC deficiency: complete clinical response observed in first male infant to receive ECUR-506 and complete 24-week Phase 1/2 study (852)
<ul>
<li>Date/Time: Tuesday, May 13, 6:00 p.m. - 7:30 p.m. ET</li>
<li>Location: Poster Hall, Hall I2</li>
<li>Presenter: Gabriel Cohn, M.D., MBA, Chief Medical Officer, iECURE</li>
</ul>
Symposium Title: Advances In Genome Editing: Novel Large DNA Insertion Technologies and Their Potential Towards Curative Therapies
<ul>
<li>Date/Time: Wednesday, May 14, 8:00 a.m. – 9:40 a.m. ET</li>
<li>Location: New Orleans Theater B</li>
<li>iECURE Title: OTC-HOPE: The first in-vivo, liver directed, AAV-mediated, gene insertion clinical trial in infants</li>
<li>iECURE Presenter: Gabriel Cohn, M.D., MBA, Chief Medical Officer, iECURE</li>
</ul>
ESHG Details:
Oral Presentation Title: Initial clinical results from the first in vivo, liver directed, AAV-mediated gene insertion study with ECUR-506 in neonatal OTC deficiency: complete clinical response in first male infant to complete 24-week Phase 1/2 study (C27.05)
<ul>
<li>Date/Time: Monday, May 26, 11:30 a.m. – 11:45 a.m. CEST</li>
<li>Location: Brown 3</li>
<li>Presenter: Julien Baruteau, M.D., Ph.D., University College London Great Ormond Street Institute of Child Health</li>
</ul>
Exhibition Booth
<ul>
<li>Dates: Saturday, May 24 – Tuesday, May 27</li>
<li>Location: Hall 4, Booth #232</li>
</ul>

DTIL

iECURE Announces It Will Present Initial OTC-HOPE Clinical Data of ECUR-506 In Ornithine Transcarbamylase Deficiency At American Society of Gene and Cell Therapy Annual Meeting May 12 – 17, 2025 In New Orleans

<ul>
<li>S-wind technology to be used in hybrid full-sized trucks,&nbsp;SUVs</li>
<li>Enables peak performance with enhanced efficiency in a compact package</li>
<li>PACE-awarded S-wind technology increases scalability and reduces costs</li>
</ul>

BorgWarner To Supply 400V SW130 eMotor To North American OEM; Financial Terms Not Disclosed

Barrington Research analyst Vincent Colicchio maintains Barrett Business Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) with a Outperform and maintains $45 price target.

Price Target

BBSI

Barrington Research Maintains Outperform on Barrett Business Services, Maintains $45 Price Target

<a href="https://www.benzinga.com/money/etoro-review">Trading platform eToro</a> on Tuesday announced it is seeking a valuation of up to $5 billion in its initial public offering on the Nasdaq, as it launches the roadshow for a 10 million Class A share sale.
Shares will be priced between $46 and $50 and trade under the ticker ETOR, <a href="https://www.etoro.com/en-us/news-and-analysis/latest-news/press-release/etoro-announces-launch-of-initial-public-offering/#:~:text=New%20York%2C%20May%205%2C%202025,offered%20by%20certain%20existing%20stockholders">according</a> to the company&#8217;s filing.
This estimate assumes a standard tech IPO float of roughly 10% of total shares. 
Some analysts, using more conservative assumptions about the public float, estimate the valuation could land closer to $4 billion. 
The final figure will depend on pricing and the number of shares outstanding once the offering is completed.
The offering includes 5 million new shares from eToro and 5 million from existing shareholders, with an additional 1.5 million shares available to underwriters via an over-allotment option. 
If fully subscribed at the top of the range, the IPO could raise up to $575 million.
eToro is a prominent multi-asset investment platform offering trading in stocks, ETFs, cryptocurrencies and commodities.
It launched crypto trading in 2013, long before most traditional fintech competitors, and has become a key player in the retail digital asset space, especially in Europe and parts of Latin America.
The company's move to go public comes after it canceled a planned SPAC merger with FinTech Acquisition Corp V in 2022, which would have valued the company at $10.4 billion. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45203946/binance-founder-changpeng-zhao-recounts-prison-hardships-i-was-scared-my-cellmate-had-a-sentence-for-murdering-two-guys-at-once">Binance Founder Changpeng Zhao Recounts Prison Hardships: &#8216;I Was Scared, My Cellmate Had A Sentence For Murdering Two Guys At Once&#8217;</a>
That deal collapsed amid cooling market conditions and regulatory scrutiny of crypto-affiliated companies.
In going public now, eToro joins a small group of crypto-integrated platforms that have listed on U.S. exchanges. 
Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) went public via a direct listing in April 2021 at an $86 billion valuation, while Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) raised $2.1 billion in its July 2021 IPO, riding a surge of interest in crypto and meme stock trading.
Unlike Coinbase, which focuses exclusively on digital assets, eToro offers exposure to both traditional and crypto markets through social investing features and copy trading, allowing users to mirror the trades of top investors. 
The platform currently supports trading in more than 80 cryptocurrencies, including Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>).
The listing will test renewed public investor appetite for consumer-facing fintech and crypto-aligned platforms, following a two-year slump in tech IPOs and multiple enforcement actions across the crypto sector.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45199299/ripple-commits-25m-to-us-teachers-and-classrooms-via-rlusd-stablecoin">Ripple Commits $25M To US Teachers And Classrooms Via RLUSD Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

COIN

HOOD

eToro Eyes $5B Valuation In Nasdaq IPO, Sets Price Range At $46–$50 Per Share

Guidance

WK Kellogg Lowers FY25 Organic Net Sales Growth Guidance From (1.0)% To (2.0)% - (3.0)%

Hovde Group analyst Brendan Nosal upgrades First Savings Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSFG#NASDAQ">FSFG</a>) from Market Perform to Outperform.

FSFG

Hovde Group Upgrades First Savings Financial to Outperform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Compass Point analyst Joe Flynn downgraded the rating for MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from Neutral to Sell and lowered the price target from $25 to $9.5. MARA Holdings shares closed at $13.09 on Monday. <a href="https://www.benzinga.com/quote/MARA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst David Risinger downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Outperform to Market Perform and cut the price target from $550 to $503. Vertex Pharmaceuticals shares closed at $500.19 on Monday. <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jenny Ping downgraded the rating for National Grid plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGG#NYSE">NGG</a>) from Buy to Neutral. National Grid shares closed at $71.84 on Monday. <a href="https://www.benzinga.com/quote/NGG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JWedbush analyst Michael Pachter downgraded Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) from Outperform to Neutral and lowered the price target from $21 to $9. Turtle Beach shares closed at $10.76 on Monday. <a href="https://www.benzinga.com/quote/tbch/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="623" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-1024x623.png" alt="" class="wp-image-903019" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06071502/image-52.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

MARA

RDDT

TBCH

VRTX

This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) affirms FY2025 sales outlook from $540.00 million-$580.00 million to $540.00 million-$580.00 million vs $543.72 million estimate.

FSTR

L.B. Foster Affirms FY2025 Sales Guidance of $540.00M-$580.00M vs $543.72M Est

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and lowers the price target from $90 to $86.

HSIC

Barrington Research Maintains Outperform on Henry Schein, Lowers Price Target to $86

<a href="https://innoviz.tech/">Innoviz Technologies Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) (the "Company" or "Innoviz"), a leading Tier-1 direct supplier of high-performance, automotive-grade LiDAR sensors and perception software, today announced an expansion of the multi-year NRE (Non-Recurring Engineering) payment plan initially announced in December 2024. The NRE payment plan is the outcome of development activities that Innoviz has performed and will continue to perform for its key existing customers. The expansion of the NRE payment plan is expected to further bolster the Company's financial position, bringing the total cash payments anticipated from the plan to approximately $95 million from $80 million between 2025 and 2027. These payments will be incremental to revenues generated from ongoing sales of LiDAR products to existing customers and new orders coming from additional programs.

INVZ

Innoviz Technologies Expands Multi-Year Non-Recurring Engineering Payment Plan

Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Oral Delivery of Therapeutics, Today Announced That It Has Entered Into License and Supply Agreement With Aché Laboratórios Farmacêuitcos s.a (Aché) Granting Exclusive Rights to Market Tlando&#xAE; in Brazil.
The market for prescription testosterone products in Brazil is substantial and rapidly growing with compound annual growth rate (CAGR) of 34% from 2019 to 2023 and no oral testosterone therapy registered in Brazil.
"We are pleased to partner with Aché, one of the leaders in the Brazilian pharmaceutical market, to further expand the opportunity for TLANDO," said Mahesh Patel, CEO of Lipocine. "Brazil represents an important new growth market, and Aché's established commercial capabilities and proven regulatory expertise make them an ideal partner to bring TLANDO to patients in Brazil."
Under the terms of the agreement, Lipocine has received an upfront payment and is eligible to receive additional payments upon the achievement of certain regulatory milestones and royalties on net sales. Aché assumes full responsibility for the regulatory submission and approval process in Brazil.

LPCN

Lipocine Enters Into License And Supply Agreement With Aché Laboratórios Farmacêuitcos S.A Granting Exclusive Rights To Market Tlando in Brazil.

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $0.04 by 600 percent. This is a 350 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $97.79 million which missed the analyst consensus estimate of $113.16 million by 13.58 percent. This is a 21.34 percent decrease over sales of $124.32 million the same period last year.

Earnings

Earnings Misses

L.B. Foster Q1 EPS $(0.20) Misses $0.04 Estimate, Sales $97.79M Miss $113.16M Estimate

Financial Guidance
The following guidance is based on current market conditions and expectations and the information available to the Company today. For 2025 Talkspace continues to expect:
<ul>
<li>Revenue to be in the range of $220 million to $235 million</li>
<li>Adjusted EBITDA to be in the range of $14 million to $20 million</li>
</ul>

TALK

Talkspace Affirms FY2025 Sales Guidance of $220.00M-$235.00M vs $226.60M Est

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.34 by 41.18 percent. This is a 45.95 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $663.00 million which missed the analyst consensus estimate of $679.49 million by 2.43 percent. This is a 6.22 percent decrease over sales of $707.00 million the same period last year.

WK Kellogg Q1 EPS $0.20 Misses $0.34 Estimate, Sales $663.00M Miss $679.49M Estimate

Business Outlook and Financial Guidance
"The first quarter book-to-bill ratio was solidly above one and we entered the second quarter with a strong outlook given the bookings momentum. While recent tariffs have caused uncertainty related to the timing of shipments and some increased costs in the near term, we are able to take advantage of our global manufacturing footprint and supply chain to mitigate their impact while continuing to invest in the future growth of our business," concluded Dr. Gitin.
For the second quarter of 2025, IPG expects revenue of $210 million to $240 million Our revenue guidance is approximately $15 million lower than it would have been due to potential shipment delays related to tariffs. These are not order cancellations and the Company expects to fulfill these orders as it optimizes production across its global footprint. The Company expects second quarter adjusted gross margin to be between 36% and 38%, including 150 to 200 basis points of impact from tariffs, and operating expenses of $86 million to $88 million. IPG anticipates delivering adjusted earnings per diluted share in the range of -$0.05 to $0.25 and adjusted EBITDA in the range of $16 million to $31 million.

IPGP

IPG Photonics Q2 Outlook: Adj EPS $(0.05)-$0.25 vs $0.31 Est; Sales $210.000M-$240.000M vs $242.19M Est

Buybacks

HESM

Hess Midstream LP Signs Accretive $200M Repurchase From Sponsors And Public

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $38.90 million which beat the analyst consensus estimate of $37.42 million by 3.97 percent. This is a 12.21 percent increase over sales of $34.67 million the same period last year.

Comments

SIGNA Sports United

Vendite allo scoperto

SIGNA Sports United (OTC:SSUNF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO